Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression

Oncogene

Volumn 29, Issue 21, 2010, Pages 3153-3162

  Li, P ^a   Wang, D ^a   Yao, H ^a,e   Doret, P ^a   Hao, G ^b   Shen, Q ^a   Qiu, H ^c   Zhang, X ^d   Wang, Y ^a,c   Chen, G ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

HDAC2; Histone citrullination; Histone deacetylation; P53; PAD4

Indexed keywords

AMIDINE; ARGININE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HISTONE; HISTONE DEACETYLASE 2; HYDROXAMIC ACID DERIVATIVE; LYSINE; PROTEIN ARGININE DEIMINASE; PROTEIN ARGININE DEIMINASE 4; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CANCER CELL; CANCER GROWTH; CITRULLINATION; CONTROLLED STUDY; DEACETYLATION; DISSOCIATION; DNA DAMAGE; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION;

ARGININE; CELL LINE, TUMOR; CITRULLINE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HISTONE DEACETYLASE 2; HISTONES; HUMANS; HYDROLASES; LYSINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952954497     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.51     Document Type: Article

References (38)

1. An W, Kim J, Roeder RG. (2004). Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117: 735-748.
2. Arita K, Hashimoto H, Shimizu T, Nakashima K, Yamada M, Sato M. (2004). Structural basis for Ca(2+)-induced activation of human PAD4. Nat Struct Mol Biol 11: 777-783.
3. Baek HJ, Malik S, Qin J, Roeder RG. (2002). Requirement of TRAP/mediator for both activator-independent and activator-dependent transcription in conjunction with TFIID-associated TAF(II)s. Mol Cell Biol 22: 2842-2852.
4. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD et al. (2001). Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8: 1243-1254.
5. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z et al. (2007). High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837.
6. Bedford MT, Clarke SG. (2009). Protein arginine methylation in mammals: who, what, and why. Mol Cell 33: 1-13.
7. Berger SL. (2007). The complex language of chromatin regulation during transcription. Nature 447: 407-412.
8. Causey CP, Thompson PR. (2008). An improved synthesis of haloaceteamidine-based inactivators of protein arginine deiminase 4 (PAD4). Tetrahedron Lett 7: 4383-4385.
9. Chang X, Han J. (2006). Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog 45: 183-196.
10. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z. (2009). Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer 9: 40.
11. Cuthbert GL, Daujat S, Snowden AW, Erdjument-Bromage H, Hagiwara T, Yamada M et al. (2004). Histone deimination antagonizes arginine methylation. Cell 118: 545-553.
12. Dannenberg JH, David G, Zhong S, van der Torre J, Wong WH, Depinho RA. (2005). mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival. Genes Dev 19: 1581-1595.
13. Espinosa JM, Emerson BM. (2001). Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 8: 57-69.
14. Fischle W, Wang Y, Allis CD. (2003). Histone and chromatin crosstalk. Curr Opin Cell Biol 15: 172-183.
15. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. (2004). Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241-1246.
16. Harms KL, Chen X. (2007). Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 67: 3145-3152.
17. Harris SL, Levine AJ. (2005). The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908.
18. Ho J, Benchimol S. (2003). Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 10: 404-408.
19. Jenuwein T, Allis CD. (2001). Translating the histone code. Science 293: 1074-1080.
20. Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE et al. (2006). Structural basis of DNA recognition by p53 tetramers. Mol Cell 22: 741-753.
21. Klose RJ, Zhang Y. (2007). Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 8: 307-318.
22. Kornberg RD, Lorch Y. (1999). Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98: 285-294.
23. Kouzarides T. (2007). Chromatin modifications and their function. Cell 128: 693-705.
24. Laptenko O, Prives C. (2006). Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 13: 951-961.
25. Levesque AA, Eastman A. (2007). p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor? Carcinogenesis 28: 13-20.
26. Li B, Carey M, Workman JL. (2007). The role of chromatin during transcription. Cell 128: 707-719.
27. Li P, Yao H, Zhang Z, Li M, Luo Y, Thompson PR et al. (2008). Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol 28: 4745-4758.
28. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. (1997). Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389: 251-260.
29. Luo J, Su F, Chen D, Shiloh A, Gu W. (2000). Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377-381.
30. Marks PA, Breslow R. (2007). Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84-90.
31. Minucci S, Pelicci PG. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
32. Shi Y, Downes M, Xie W, Kao HY, Ordentlich P, Tsai CC et al. (2001). Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. Genes Dev 15: 1140-1151.
33. Shilatifard A. (2006). Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem 75: 243-269.
34. Strahl BD, Allis CD. (2000). The language of covalent histone modifications. Nature 403: 41-45.
35. Turner BM. (2000). Histone acetylation and an epigenetic code. Bioessays 22: 836-845.
36. Vogelstein B, Lane D, Levine AJ. (2000). Surfing the p53 network. Nature 408: 307-310.
37. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L et al. (2004). Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306: 279-283.
38. Yao H, Li P, Venters BJ, Zheng S, Thompson PR, Pugh BF et al. (2008). Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem 283: 20060-20068.